Assessment of human abuse potential of preladenant (a centrally-acting A2A antagonist) compared to phentermine and placebo in recreational stimulant users
Kerri A. Schoedel, Joanna Udo de Haes(Merck & Co., Inc., Rahway, NJ, USA (United States)), Naama Levy‐Cooperman(Vale (Canada)), Kristin L. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pat Larson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Basseches(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward M. Sellers(University of Toronto), Mattew Troyer(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Hewitt(Glasgow Royal Infirmary)
Cited by 1
Related Papers
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
MALIGNANT DISEASE IN CHILDHOOD AND DIAGNOSTIC IRRADIATION IN UTERO
|The Lancet|1956|569